Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zevra Therapeutics, Inc. (ZVRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, Zevra uses current reports on Form 8-K and other periodic filings to communicate material events, financial results, and governance changes related to its rare disease business.
Investors can review Form 8-K filings in which Zevra reports quarterly financial results and corporate updates, including revenue from its commercial products for Niemann-Pick disease type C and certain urea cycle disorders, operating expenses, and information about conference calls and webcasts. Other 8-K filings detail matters such as the resignation and transition of key officers, appointment of interim financial leadership, and board-level changes, along with summaries of related agreements and compensation terms.
These filings also document equity inducement awards granted under Zevra’s employment inducement award plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing transparency into stock option grants to new employees. Together with annual and quarterly reports (when available), the filings offer a structured view of Zevra’s financial condition, capital structure, and risk disclosures as it advances therapies like MIPLYFFA and OLPRUVA and develops candidates such as celiprolol.
On Stock Titan, SEC documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Real-time updates from EDGAR help users see new Zevra filings as they appear, while specialized views of Forms 3, 4, and 5 make it easier to track insider transactions. For long-form reports such as 10-K and 10-Q, AI-generated highlights can help users quickly identify important sections on revenue drivers, research and development spending, and material risks related to Zevra’s rare disease portfolio.
Form 144 discloses a planned sale of 105,625 shares of common stock, with an aggregate market value of $950,625.00. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ around 02/02/2026.
The securities were acquired on 01/31/2026 as restricted stock units from the issuer, with the same date listed for payment and the nature of payment marked as N/A. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
Zevra Therapeutics (symbol ZVRA) has a planned insider sale of shares under Rule 144. A holder intends to sell 4,750 shares of the company’s common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of
The shares were acquired as restricted stock units from the issuer on
A shareholder of the issuer of ZVRA has filed a Rule 144 notice to sell 14,000 shares of common stock. The planned sale, through Morgan Stanley Smith Barney LLC on the NASDAQ, has an aggregate market value of $124,040.00.
The 14,000 shares were acquired from the issuer as restricted stock units dated 01/30/2026, with the same date listed for payment. The notice also reports 56,297,535 shares of the issuer’s common stock outstanding and confirms the seller represents having no undisclosed material adverse information.
A holder of ZVRA common stock filed a Rule 144 notice to sell 4,080 shares, with an aggregate market value of $36,148.80. The planned sale is through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/30/2026.
The shares come from restricted stock units acquired from the issuer on 01/30/2026 in the same amount of 4,080 units. The form notes that there are 56,297,535 ZVRA common shares outstanding at the time of this notice.
Zevra Therapeutics (symbol ZVRA) has a Form 144 filing indicating a planned insider sale of common stock. The notice covers 13,875 common shares to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $122,932.50. The planned sale is listed for 01/30/2026 on the NASDAQ market. The shares were acquired from the issuer on 01/30/2026 as restricted stock units, in a non-cash transaction described as “N/A” for the nature of payment. The filing also states that the person selling the securities represents they are not aware of any undisclosed material adverse information about the issuer’s operations.
ZVRA filed a notice for a planned insider stock sale under Rule 144. The person named in the filing intends to sell 4,533 shares of Zevra Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $40,162.38 on the NASDAQ.
The shares are being sold after acquisition as restricted stock units on 01/30/2026. Zevra Therapeutics had 56,297,535 common shares outstanding, which is a baseline figure for the company’s equity.
Zevra Therapeutics former CFO & Treasurer Clifton R. LaDuane reported equity transactions tied to his departure on December 31, 2025. On that date, 140,667 shares of common stock were issued at $0 upon vesting of previously granted restricted stock units and performance stock units. After this issuance, he held 192,028 common shares.
Also on December 31, 2025, 48,513 common shares were withheld at $8.96 per share to cover withholding taxes related to the vesting, leaving him with 143,515 common shares beneficially owned directly. The filing shows 86,667 and 34,000 restricted stock units and 20,000 performance stock units converting into common stock, with all such units fully vested and accelerated upon his departure, and no derivative units remaining.
Zevra Therapeutics, Inc. reported a leadership change in its finance organization. The board appointed Timothy Sangiovanni, currently Senior Vice President, Finance and Corporate Controller and principal accounting officer, to serve as interim principal financial officer effective January 1, 2026. He has held senior finance and reporting roles at the company since 2015. The company noted that there was no change to Mr. Sangiovanni’s compensation arrangements in connection with this interim appointment.
Zevra Therapeutics, Inc. director Alicia Secor has filed an initial insider ownership report indicating that she does not beneficially own any of the company’s securities. The filing is made as a Form filed by one reporting person in her capacity as a director of Zevra Therapeutics.
The event date for this disclosure is 12/02/2025, and the form is signed by an attorney-in-fact on her behalf. The remarks section explicitly states that no securities are beneficially owned, meaning there are currently no reported direct or indirect holdings by this director.
Zevra Therapeutics, Inc. reported that its Chief Financial Officer, Treasurer, and principal financial officer, R. LaDuane Clifton, has decided to resign effective December 31, 2025 to pursue other professional opportunities. The company and Mr. Clifton entered into a Separation Agreement under which he will receive separation benefits after his departure, including cash payments equal to 12 months of his annual base salary, an annual bonus equal to 40% of his base salary, up to 12 months of company-paid COBRA continuation coverage, and full vesting of his outstanding equity awards. These benefits are conditioned on his continued compliance with non-disparagement, confidentiality, non-competition, and non-solicitation covenants. Zevra has begun a search process to identify a new chief financial officer and issued a press release describing these matters.